Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 5/20 | 1.00 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.74 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | GFER | P55789 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | CRHBP | P24387 | 1/20 | 0.57 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.57 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5467209 | 0.85 | VCAM1 (0.74) | VCAM1NPBWR1MCHR1L3MBTL1CRHBP | |
| SCHEMBL8337970 | 0.84 | VCAM1 (0.73) | VCAM1NPBWR1MCHR1L3MBTL1RAB9A | |
| SCHEMBL3622325 | 0.83 | VCAM1 (0.76) | VCAM1NPBWR1MCHR1L3MBTL1ATM | |
| SCHEMBL6055083 | 0.83 | VCAM1 (0.69) | VCAM1NPBWR1MCHR1L3MBTL1MAPK1 | |
| SCHEMBL16371970 | 0.82 | VCAM1 (0.70) | VCAM1L3MBTL1RAB9AMEN1KMT2A | |
| SCHEMBL31347245 | 0.82 | VCAM1 (0.69) | VCAM1NPBWR1MCHR1L3MBTL1RAB9A | |
| SCHEMBL8049609 | 0.82 | RAB9A (0.85) | VCAM1L3MBTL1RAB9AATMMAPK1 | |
| SCHEMBL22659755 | 0.80 | VCAM1 (0.67) | VCAM1NPBWR1MCHR1L3MBTL1RAB9A | |
| SCHEMBL15823829 | 0.80 | L3MBTL1 (0.67) | VCAM1L3MBTL1RAB9AGFER | |
| SCHEMBL5474254 | 0.79 | MEN1 (0.67) | VCAM1NPBWR1MCHR1MAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3218357-B1 | 3,4-DIAMINOBENZENESULFONAMIDE DERIVATIVES FOR INHIBITING CELL DEATH | VIB VZW (BE) | 2020-04-29 | — | — | EP | disclosed |
| US-9862678-B2 | 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death | VIB VZW (BE) | 2018-01-09 | — | — | US | disclosed |
| US-20170313653-A1 | 3,4-DIAMINOBENZENESULFONAMIDE DERIVATIVES FOR INHIBITING CELL DEATH | VIB VZW (BE) | 2017-11-02 | — | — | US | disclosed |
| EP-3218357-A1 | 3,4-DIAMINOBENZENESULFONAMIDE DERIVATIVES FOR INHIBITING CELL DEATH | VIB vzw (BE) | 2017-09-20 | — | — | EP | disclosed |
| EP-3019493-B1 | MODIFIED BET-PROTEIN INHIBITING DIHYDROCHINOXALINONES AND DIHYDROPYRIDOPYRAZINONES | Bayer Pharma AG (DE) | 2017-06-14 | — | — | EP | disclosed |
| US-20160176867-A1 | MODIFIED BET-PROTEIN-INHIBITING DIHYDROQUINOXALINONES AND DIHYDROPYRIDOPYRAZINONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-23 | — | — | US | disclosed |
| US-20160176867-A1 | MODIFIED BET-PROTEIN-INHIBITING DIHYDROQUINOXALINONES AND DIHYDROPYRIDOPYRAZINONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-23 | — | — | US | disclosed |
| WO-2016075330-A1 | 3,4-DIAMINOBENZENESULFONAMIDE DERIVATIVES FOR INHIBITING CELL DEATH | VIB VZW (BE) | 2016-05-19 | — | — | WO | disclosed |
| EP-3019493-A1 | MODIFIED BET-PROTEIN-INHIBITING DIHYDROQUINOXALINONES AND DIHYDROPYRIDOPYRAZINONES | Bayer Pharma Aktiengesellschaft (DE) | 2016-05-18 | — | — | EP | disclosed |
| EP-2103613-B1 | QUINOXALINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2016-02-17 | — | — | EP | disclosed |
| WO-2011006567-A1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | MERCK PATENT GMBH (DE) | 2011-01-20 | — | — | WO | disclosed |
| US-20100048556-A1 | QUINOXALINE DERIVATIVES | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
| US-20100048556-A1 | QUINOXALINE DERIVATIVES | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
| US-20100048556-A1 | QUINOXALINE DERIVATIVES | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2103613-A1 | QUINOXALINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-09-23 | — | — | EP | disclosed |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | ASTEX THERAPEUCTICS, LIMITED (US) | 2007-06-14 | — | — | US | disclosed |
| CN-1845734-A | Benzimidazole derivatives and their use as protein kinases inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2006-10-11 | — | — | CN | disclosed |
| EP-1648426-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Astex Therapeutics Limited (GB) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005002552-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
| WO-2004022528-A2 | ARYLGLYCINE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS | NPS ALLELIX CORP. (CA) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313653-A1 | 3,4-DIAMINOBENZENESULFONAMIDE DERIVATIVES FOR INHIBITING CELL DEATH | CASP3, BAX, TMBIM6 | VCAM1 3013/4885NPBWR1 2728/4885MCHR1 4662/4885 |
| US-20160176867-A1 | MODIFIED BET-PROTEIN-INHIBITING DIHYDROQUINOXALINONES AND DIHYDROPYRIDOPYRAZINONES | BRD4, BRDT, BET1 | VCAM1 1919/4885NPBWR1 3742/4885MCHR1 4776/4885 |
| US-20100048556-A1 | QUINOXALINE DERIVATIVES | PDE9A, ADCY9, PRMT9 | VCAM1 4044/4885NPBWR1 1471/4885MCHR1 1641/4885 |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | CDK1, AURKA, CDK2 | VCAM1 2646/4885NPBWR1 4767/4885MCHR1 4762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.